Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And what makes you think that management is going to share it with you if they do get a big settlement. To a pink sheet, investors like you (and me) are seed money and suckers to be left in the dust.
Even if there is a large settlement, what makes you think that management is going to be so quick to share it with small,bretail shareholders? This is a pink sheet.
Has the fat lady really sung already, Leirum? I don't think so.
All those preferred shares can be converted in an instant,and when the real pump starts, they will be, in my humble opinion.
You guys are in for a very rude awakening.
When all is said and done, JNJ will be standing unaffected and DECN will be but a memory, and a bitter one to some.
This is America, Dusde.
The Solicitor General works for JNJ.
That's a complex question. I do feel the US government has come under the undue influence of many of the countries behemoth companies.
This is a fact: JNJ did not become the behemoth it has become by losing lawsuits to pissant companies like DECN.
EDIT: And if it does, those pissant companies had best watch out for revenge.
This is America.
JNJ and its legal team has so consistently (and erroneously) been portrayed as buffoons on this thread that many readers have come to accept it as fact.
When the very powerful JNJ legal team finally rears its head to put this nuisance case to rest, some advocates of DECN may very well be in for a shock.
You'll find out at the same moment you find DECN trading at less than a dime.
Yeah, Alydyr, you know as well as dankdamp that DECN is about to go up 50,000%. Don't you?
I understand he's an expert in radio commercial placement.
So then you acknowledge that there are NO facts on this bulletin board, only opinions, and not well informed ones at that.
Which filing?
I simply asked with what resources they are the going to acquire another company. Will they buy it with stock, or from all the money they've been making selling on Ebay, or from the money they make selling preferred shares?
Did whichever filing the said they would be acquiring another company include the disclaimer that the filing contained forward looking statements?
They are acquiring another company, developing new products, expanding their sales efforts into Europe and China, etc. Ity's a fair question to ask how they are paying for all that.
Do I think companies, including possibly DECN, sometimes lie? The answer is definitely yes.
Do you believe companies that companies never lie or deliberately mislead, Viking?
PS - How many employees does DECN have? How many are on the sales team? The research team? Their acquisition team?
With what are they going to pay for this acquisition, Leirum?
Yous sound so much more like Jeremiah - or Cassandra - than like Lazarus.
I did not say he made it up. He himself said, " . . . it appears . . ." rule 35 has been invoked. And then many posts followed presuming why rule 35 was invoked without knowing why or if it was invoked. Just conjecture.
Price remains .18ish.
Fiction prevails.
It's not news. Someone posted it as a possibility and within two or three following posts it magically transformed into fact. And you expect the price to rise due to a couple of posts on a bulletin board.
Are you that seller, Lazarus?
You seem like you're on a mission.
Actually, I think it's theatrics that will give the stock a boost,but it won't hold. All decn has is theatrics.
The gentle coo of sweet nothings.
Thanks for reposting the press release of last week. I feel richer every time I read it.
How many times is the same thing going to be repeated over and over - decn beat jnj three times in court!!! -while management refuses to reveal financials and the price continues to languish at 20% of its high only about 16 months ago.
decn beat jnj three times in court!
decn beat jnj three times in court!
decn beat jnj three times in court!
Not a person here is in the black.
DECN is fairly valued at .18, and when it gets down to a dime, it will be fairly valued at a dime.
Ain't nobody's fault but decn's.
As I mentioned earlier, it's nice to see your incisive view again blue. You always cut to the bone.
How is this different than saying "Great post, Leirum"?
How is this different than saying "Thanks for the explanation, Mr. S."?
It's not. It's on topic and its part of the conversation.
JNJ is obviously not sweating it.
It is of minor significance to JNJ.
You do some wonderful and real due diligence, Alydyr.
People ignore your posts at their peril.
It's really not all that relevant to JNJ shareholders. Even DECNs most ardent defenders recognize that any fine JNJ might have to pay to DECN, if any, will not be much - probably under $10 Mil, which is chump change to JNJ, not enough to effect JNJs share price.
Furthermore, the pr you attached is not an objective account of the proceedings. That was written by management of DECN. An objective reporter might describe the legal proceedings far differently.
As far as JNJ is concerned, the DECN case is a minor nuisance.
Only in the short term price.
Yes indeed!! All of that, and you showing up! You seem to be a very experienced stock trader and I trust your "instincts". I see brief a rise in price in DECN's near future!
The presence of Pete is a good omen that a brief rise in price is afoot.
Lately, there has been concerns over a potential bubble in the biotechnology sector. The sector has been one of the biggest beneficiaries of the six-year bull market in the U.S. Recently, though, analysts at Credit Suisse said that the biotech sector is far from being overbought.
According to MarketWatch, Credit Suisse analyst Ravi Mehrotra said in a research note to investors last week that there are some optics suggesting that we are in a biotech bubble, however, a multi-year rally does not make a bubble. Mehrotra believes that the industry has evolved over the past three years and there is a potential now for companies to bring blockbuster drugs to market.
Mehrotra does have a valid point. There are many companies in the biotech sector that have the potential to bring blockbuster drugs to the market and create significant value for shareholders. The question is whether investors can find the winners among the vast biotechnology sector.
For finding gems in the biotechnology sector, investors need to focus on emerging companies that have significant potential and are trading at reasonable levels. One such company is Alachua, Florida-based CTD Holdings Inc. (OTCQB:CTDH), which is a family of biotechnology growth companies based on cyclodextrin chemistry.
CTDH’s divisions distribute and manufacture the trademarked Trappsol® and Aquaplex® cyclodextrins, cyclodextrin derivatives, and cyclodextrin complexes for biotechnology and life science companies involved in research, pharmaceutical, medical device, cosmetics and nutrition markets.
On Thursday, CTDH announced that it has amended its agreement with Medical Need Europe (MNE). Under the altered agreement, MNE will be the exclusive distributor in Europe of Trappsol® CycloTM and any new cyclodextrin-based Orphan Drug Designated treatments developed by CTDH.
MNE is based on Stockholm, Sweden. It already has an exclusive distributorship of Trappsol® CycloTM for the treatment of Niemann-Pick Type C, which is a rare and fatal disease found mainly in children.
Back in March, CTDH had also selected Accenture (NYSE:ACN) to provide it with data-driven clinical trial strategy and design through its Accelerated R&D Services. Dr. Tate noted that Accenture is working with CTDH at a time when the company is devising its clinical development program that will establish the safety and efficacy of Trappsol® CycloTM for the treatment of Niemann-Pick Type C disease.
http://www.baystreet.ca/articles/stockstowatch.aspx?id=928
This is bigger than you think, P4K!
Not only is the court going to reverse the glucose strip patents to DECN, JNJ is going to have to turn over ALL of its patents to DECN.
Leirum can back me up on this.
In less than two weeks, our little .17 stock is going to be worth $100+.
This is money in the bank.
Since when is repetition a problem?
Let's hear about those three court victories again, Mister S!
It's all irrelevant . . . on April 14 it is going to be announced that, with the help of those preferred shares, DECN ISBUYING JNJ!!!!!
According to my partner, after the settlement DECN will be buying JNJ.
Yes, that's what I said . . . DECN IS BUYING JNJ.
You heard it here first.
I have no idea if decn is about declare bankruptcy or not, but if they were, why would you expect them to have declared their cash position? They don't declare anything except their inability to file on time.
You do great due diligence, Alydyr.
That's not exactly and "independent" auditor.
That's a sweeping statement and only an opinion. Aggressive pr's are sometimes just ploys.